Novartis to acquire German Biotech MorphoSys for $2.9B, Expanding Cancer Drug Pipeline
Novartis plans to purchase MorphoSys for $2.9 billion, allowing it to own pelabresib, which is a treatment being investigated for a rare type of bone marrow cancer.
( 1
min )